Long-Term Remission of Primary Bone Marrow Diffuse Large B-Cell Lymphoma Treated with High-Dose Chemotherapy Rescued by In Vivo Rituximab-Purged Autologous Stem Cells

الملخص EN

Primary bone marrow diffuse large B-cell lymphoma (DLBCL) is a rare type of extranodal lymphoma with poor prognosis.

Here, we report a case of primary bone marrow DLBCL successfully treated with high-dose chemotherapy and rescued by in vivo rituximab-purged autologous stem cells.

A 39-year-old woman visited our hospital because of anemia.

Bone marrow examination revealed a large B-cell lymphoma invasion.

An 18F-fluorodeoxyglucose positron emission tomography scan revealed disseminated bone marrow uptake without evidence of dissemination at other sites.

These findings led to a diagnosis of primary bone marrow DLBCL.

Our patient underwent R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and achieved complete remission.

Subsequently, she received high-dose chemotherapy with an in vivo rituximab-purged autologous stem cell transplant.

Seven years have passed since the transplantation, and she remains in remission.

This suggests that transplantation of an in vivo rituximab-purged autograft is a promising strategy for primary bone marrow DLBCL.